Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2003
10/23/2003WO2003086394A1 Inhibitors of akt activity
10/23/2003WO2003086390A1 Imidazole compounds as anti-inflammatory and analgesic agents
10/23/2003WO2003086386A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures
10/23/2003WO2003086385A1 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss
10/23/2003WO2003086384A1 Stabilized ascorbic acid derivatives
10/23/2003WO2003086381A1 Ansamycin formulations and methods for producing and using same
10/23/2003WO2003086377A1 Amide derivatives
10/23/2003WO2003086373A1 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
10/23/2003WO2003086371A2 Use of ep4 receptor ligands in the treatment of il-6 involved diseases
10/23/2003WO2003086344A1 Antibiotic product, use and formulation thereof
10/23/2003WO2003086325A2 Cyanamides useful as reversible inhibitors of cysteine proteases
10/23/2003WO2003086324A2 Preparation and use of a stable formulation of allosteric effector compounds
10/23/2003WO2003086318A2 Improved prodrugs of cc-1065 analogs
10/23/2003WO2003086315A2 Tyrosine kinase inhibitors
10/23/2003WO2003086314A2 Tyrosine kinase inhibitors
10/23/2003WO2003086311A2 Methods for treating tweak-related conditions
10/23/2003WO2003086309A2 NF-κB INHIBITORS
10/23/2003WO2003086306A2 5ht2c receptor modulators
10/23/2003WO2003086294A2 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
10/23/2003WO2003086289A2 Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
10/23/2003WO2003086288A2 Bicyclic amides
10/23/2003WO2003086287A2 Compounds and methods for inducing apoptosis in proliferating cells
10/23/2003WO2003086279A2 Inhibitors of akt activity
10/23/2003WO2003086175A2 Compositions and methods for the therapy and diagnosis of lung cancer
10/23/2003WO2003086102A2 Method for the production of potato juice products by means of food technology
10/23/2003WO2003086097A1 Composition for modulating a physiological reaction or inducing an immune response
10/23/2003WO2003072812A3 Method and nucleic acids for the analysis of colorectal cell proliferative disorders
10/23/2003WO2003057252A8 Human mast cell-expressed membrane proteins
10/23/2003WO2003057147A3 Useful aroyl pyrrole heteroaryl methanones and methanols
10/23/2003WO2003055848A3 Urea derivatives as vr1- antagonists
10/23/2003WO2003053325A3 Microencapsulation of drugs by solvent exchange
10/23/2003WO2003043966A3 Clusianon isomers and use thereof
10/23/2003WO2003035047A3 Combinations comprising a selective cyclooxygenase-2 inhibitor
10/23/2003WO2003029410A3 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER
10/23/2003WO2003027094A3 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
10/23/2003WO2003020279A3 Compositions and methods of treatment of cancer
10/23/2003WO2003016466A3 ANTI-Aβ ANTIBODIES
10/23/2003WO2003011908A3 Mutant forms of the tgf-b type ii receptor which bind all tgf-b isoforms and the use thereof
10/23/2003WO2003007954A3 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
10/23/2003WO2003000226A3 Pharmaceutical compositions containing polymer and drug assemblies
10/23/2003WO2002102312A3 Combination therapy of gamma-interferon and b cell specific antibodies
10/23/2003WO2002097042A3 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same
10/23/2003WO2002094248A3 Composition and use of substances for stabilising amino acids containing sulphur and/or for inhibiting the continuous formation of amino acids containing sulphur in a blood sample
10/23/2003WO2002092015A3 Reagents and methods for modulating dkk-mediated interactions
10/23/2003WO2002081521A8 Osteoprotegerin in milk
10/23/2003WO2002077199A3 Methods and products related to fgf dimerization
10/23/2003WO2002074034A3 Novel medicament compositions based on anticholinergic agents and endothelin antagonists
10/23/2003WO2002070556A9 POLYPEPTIDE OF A P53 PROTEIN-SPECIFIC MURINE Α/β T-CELL RECEPTOR, NUCLEIC ACIDS CODING THEREFOR AND USE THEREOF
10/23/2003WO2002069793A8 Extracorporeal blood processing information management system
10/23/2003WO2002046384A3 Kinases and phosphatases sequences, and use thereof
10/23/2003WO2002044321A3 Rna interference mediating small rna molecules
10/23/2003WO2002042272A8 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
10/23/2003WO2002036806A3 Expression vectors able to elicit improved immune response and methods of using same
10/23/2003WO2001096376A9 Pro-apoptotic fragments of the dengue virus envelope glycoproteins
10/23/2003WO2001047562A8 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
10/23/2003WO2001045641A8 Inhibitors of thrombin induced platelet aggregation
10/23/2003WO2001027635A8 Multiwell scanner and scanning method
10/23/2003WO2001000812A8 22012, a novel human carboxypeptidase
10/23/2003WO2001000811A8 17867, a novel human aminopeptidase
10/23/2003US20030199701 Treating under hydrolyzing conditions a hydantoin compound to form an alpha-amino acid derivative
10/23/2003US20030199698 Anticoagulants such as 2'-tert-butylaminosulfonylbiphenyl-4-yl-(3-(5-methyl-1,2,4-oxadiazol-3 -yl)benzyl)(2-cyanoethyl) carbamate, used for prophylaxis of cardiovascular disorders
10/23/2003US20030199691 2-(2,6-dichlorophenyl)-diarylimidazoles
10/23/2003US20030199689 Heterocyclic nitrogen compounds such as 1-(5-(5-Chlorothiophen -2-yl)-isoxazol-3-ylmethyl)-1H-indole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide, used as anticoagulants for prophylaxis of cardiovascular disorders
10/23/2003US20030199679 Recombinant antibodies specific for TNF-alpha
10/23/2003US20030199571 Useful in treatment and prophylaxis of conditions mediated by s-CD23 or tumor necrosis factor; autoimmune disease, inflammation, allergy
10/23/2003US20030199569 Pyrrolidine derivatives
10/23/2003US20030199568 Salt of perindopril and pharmaceutical compositions containing it
10/23/2003US20030199563 Heterocyclic containing biphenyl aP2 inhibitors and method
10/23/2003US20030199561 Boronic ester and acid compounds, synthesis and uses
10/23/2003US20030199557 Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
10/23/2003US20030199555 Indoline compounds and to pharmaceutical compositions containing them
10/23/2003US20030199554 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
10/23/2003US20030199553 Antidiabetic agents
10/23/2003US20030199552 Amide derivatives as NMDA receptor antagonists
10/23/2003US20030199551 Calcium blockers to treat proliferative vitreoretinopathy
10/23/2003US20030199550 Cyclohexane derivatives containing amine or amine oxide, useful for treating hypercholesterolemia and hyperlipemia
10/23/2003US20030199549 Novel piperidine based MCH antagonists for treatment of obesity and CNS disorders
10/23/2003US20030199548 Administering quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives containing one of the ring selected from benzene, pyridine, thienyl, furanyl, imidazolyl and triazolyl for therapy in pain management
10/23/2003US20030199547 Quinolinone derivatives containing imidazole rings is useful as anticarcinogenic agent
10/23/2003US20030199546 6-(((2S)-2-(alkoxycabonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3.4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate, or acid derivatives, useful for treating migraine, and dural protein extravasation
10/23/2003US20030199534 Kinase inhibitors
10/23/2003US20030199532 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists
10/23/2003US20030199528 Such as cis-8-(2-aminocyclohexylamino)-7-benzyl-3-methyl-1-(2-oxo-2-phenylehtyl)-3,7-dihydropurine-2,6-dione for inhibition of dipeptidyl peptidase-IV (DPP-IV); for treatment of diabetes/obesity
10/23/2003US20030199526 Pyrimidine-based compounds useful as GSK-3 inhibitors
10/23/2003US20030199525 Kinase inhibitors
10/23/2003US20030199520 Sulfonamide hydroxamates
10/23/2003US20030199519 Prodrugs of CC-1065 analogs
10/23/2003US20030199516 Methods of treating infection by drug resistant bacteria
10/23/2003US20030199515 Method for the preparation of crystalline tetrahydrobenzothiepines
10/23/2003US20030199510 Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
10/23/2003US20030199506 An enzyme inhibitor of cysteine proteases, a morpholine-4-carboxyamide 1,3,4-oxadiazole derivatives; for treating arthritis, muscular dystrophy, inflammation, tumor, glomerulonephritis, malaria, periodontal disease
10/23/2003US20030199505 Anticoagulants as inhibitors of factor Xa; treating thrombosis, or aftertreatment following angioplasty and coronary bypass operations
10/23/2003US20030199504 Anticoagulants as inhibitors of factor Xa; treating thrombosis, or aftertreatment following angioplasty and coronary bypass operations
10/23/2003US20030199502 Indoloquinazolinones
10/23/2003US20030199501 A sulfonylamino-tetrahydro(1,3)thiazolo(5,4-c)pyridinyl or benzothiazole derivatives, for treating diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia
10/23/2003US20030199499 Novel guanidinobenzamides
10/23/2003US20030199498 Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
10/23/2003US20030199497 Novel calcium receptor active molecules and method for preparing same
10/23/2003US20030199493 A dibenzofuranazepine derivatives for use as therapeutic treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, epilepsy, stroke, cerebral trauma
10/23/2003US20030199491 Quinoline derivatives having vegf inhibiting activity
1 ... 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 ... 1564